These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Recent Clinical Trials Shed New Light on the Cardiovascular Benefits of Omega-3 Fatty Acids. Kris-Etherton PM; Richter CK; Bowen KJ; Skulas-Ray AC; Jackson KH; Petersen KS; Harris WS Methodist Debakey Cardiovasc J; 2019; 15(3):171-178. PubMed ID: 31687095 [TBL] [Abstract][Full Text] [Related]
11. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting. Cziraky MJ; Watson KE; Talbert RL J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279 [TBL] [Abstract][Full Text] [Related]
12. Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease risk: current status and treatments. Reyes-Soffer G Curr Opin Endocrinol Diabetes Obes; 2021 Apr; 28(2):85-89. PubMed ID: 33481422 [TBL] [Abstract][Full Text] [Related]
13. Icosapent ethyl for reduction of persistent cardiovascular risk: a critical review of major medical society guidelines and statements. Miller M; Tokgozoglu L; Parhofer KG; Handelsman Y; Leiter LA; Landmesser U; Brinton EA; Catapano AL Expert Rev Cardiovasc Ther; 2022 Aug; 20(8):609-625. PubMed ID: 35876118 [TBL] [Abstract][Full Text] [Related]
14. National Lipid Association Scientific Statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high or very-high ASCVD risk. Orringer CE; Jacobson TA; Maki KC J Clin Lipidol; 2019; 13(6):860-872. PubMed ID: 31787586 [TBL] [Abstract][Full Text] [Related]
15. Nonstatin therapies for management of dyslipidemia: a review. Sando KR; Knight M Clin Ther; 2015 Oct; 37(10):2153-79. PubMed ID: 26412799 [TBL] [Abstract][Full Text] [Related]
16. Can pleiotropic effects of eicosapentaenoic acid (EPA) impact residual cardiovascular risk? Nelson JR; True WS; Le V; Mason RP Postgrad Med; 2017 Nov; 129(8):822-827. PubMed ID: 28974128 [TBL] [Abstract][Full Text] [Related]
17. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Chapman MJ; Ginsberg HN; Amarenco P; Andreotti F; Borén J; Catapano AL; Descamps OS; Fisher E; Kovanen PT; Kuivenhoven JA; Lesnik P; Masana L; Nordestgaard BG; Ray KK; Reiner Z; Taskinen MR; Tokgözoglu L; Tybjærg-Hansen A; Watts GF; Eur Heart J; 2011 Jun; 32(11):1345-61. PubMed ID: 21531743 [TBL] [Abstract][Full Text] [Related]
18. Long-chain omega-3 fatty acids, fibrates and niacin as therapeutic options in the treatment of hypertriglyceridemia: a review of the literature. Ito MK Atherosclerosis; 2015 Oct; 242(2):647-56. PubMed ID: 26296750 [TBL] [Abstract][Full Text] [Related]
19. Lowering triglycerides to modify cardiovascular risk: will icosapent deliver? Scherer DJ; Nicholls SJ Vasc Health Risk Manag; 2015; 11():203-9. PubMed ID: 25848301 [TBL] [Abstract][Full Text] [Related]